Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2008)	8/8/2007 3:43:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

BIOM Started with an UG today, trading above the $1 level.<g> bigcharts.marketwatch.com It announced today the signing of amended collaboration agreement related to Stimuvax with Merck KGaA. Merck KGaA is currently conducting a PIII of Stimuvax in patients with unresectable Stage III NSCLC. Under the terms of the restated agreements, Merck will have world wide marketing rights to and will be entirely responsible for the further clinical development of Stimuvax & Biomira is entitled to development and sales-based milestone payments and a royalty on net sales. Biomira retains responsibility for the manufacture of Stimuvax, & Merck will exclusively purchase Stimuvax from Biomira. The restated agreements provide Biomira with revised payments based on certain milestones related to manufacturing scale-up and process transfer. Biomira also will receive a payment of U.S. $2.5M upon clearance of the transaction with the U.S. anti-trust authorities. BIOM is expected to have enough cash to continue operation without need for further financing until the end of 2008.<g> biz.yahoo.com Bernard